-
Perphenazine: Dopamine D2 Antagonist in Neuropharmacology Re
2026-06-22
Perphenazine is a well-characterized dopamine D2 receptor antagonist with distinct affinity for multiple neurotransmitter receptors. It reliably induces mitochondria-mediated cell death in neuronal cell lines and suppresses opioid tolerance in animal models. Recent studies highlight its emerging role in host-directed antibacterial strategies.
-
Mouse Tissue Lysis Kit (K1038): Protocol and Workflow Guide
2026-06-22
The Mouse Tissue Lysis Kit (K1038) addresses the challenge of preparing mouse tissue lysates for genotyping assays by enabling rapid lysis and direct DNA template preparation, thus eliminating traditional extraction steps. It is intended solely for research in molecular biology and is not suitable for diagnostic or medical use.
-
LY2109761: Advancing TGF-β Dual Inhibition in Translational
2026-06-21
Explore how LY2109761, a potent TGF-β receptor type I/II dual inhibitor, enables precision modulation of the Smad signaling axis for anti-tumor and anti-fibrotic research. This thought-leadership article bridges mechanistic insight with strategic guidance, connecting recent discoveries in pancreatic cancer biology with the emerging translational potential of selective TβRI/II kinase inhibition. Featuring critical appraisal of the latest studies, protocol parameters, and a vision for next-generation combinatorial strategies, we position LY2109761 as a cornerstone for high-impact experimental design.
-
Tumor-Targeted PAD4 Inhibitors Suppress H3cit-NET Pathway In
2026-06-20
A recent study demonstrates that meta-phenylboronic acid–modified PAD4 inhibitors, specifically Compound 5i TFA, achieve highly selective tumor targeting by inhibiting the PAD4–H3cit–NET pathway in neutrophils. This approach offers significant advances in antitumor efficacy and immune microenvironment modulation, with minimal toxicity.
-
Clodronate Liposomes: Precision In Vivo Macrophage Depletion
2026-06-19
Clodronate Liposomes enable targeted, reproducible in vivo macrophage depletion, empowering researchers to dissect immune cell function in cancer and inflammation models. APExBIO’s formulation offers flexible dosing and administration options, making it the reagent of choice for mechanistic studies on tumor microenvironments and immunotherapy resistance.
-
Autopalmitoylation of IDH1-R132H Modulates Oncometabolite Ac
2026-06-19
This study uncovers that the cancer-associated IDH1-R132H mutation undergoes unique autopalmitoylation at cysteine 269, a modification that enhances its neomorphic function and links fatty acid metabolism to IDH1-driven tumorigenesis. These findings establish autopalmitoylation as a regulatory, druggable mechanism in IDH1-mutant cancers, with broad implications for metabolic and epigenetic research.
-
CRL4DCAF13-Mediated MeCP2 Degradation Maintains Oocyte Epige
2026-06-18
This study reveals that the CRL4DCAF13 E3 ubiquitin ligase is essential for targeting MeCP2 for degradation in growing oocytes, thereby preventing DNA hypermethylation and ensuring normal transcription. These findings advance our understanding of oocyte epigenetic regulation and have implications for ovarian aging and fertility research.
-
Cefiderocol Activity Against Resistant P. aeruginosa and Aci
2026-06-18
This large-scale European study demonstrates that cefiderocol retains high in vitro activity against Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and advanced β-lactam/β-lactamase inhibitor combinations. The findings refine our understanding of therapeutic options for multidrug-resistant Gram-negative pathogens and inform future resistance research.
-
Inhibition of Extracellular Vesicle Release in TNBC Using Ca
2026-06-17
McNamee et al. conducted a comprehensive analysis of how calpain inhibition, including the use of Calpeptin, can suppress the release of extracellular vesicles (EVs) in triple-negative breast cancer (TNBC) cells. Their findings highlight the significance of targeting EVs to limit the propagation of aggressive cancer traits, with implications for both cancer and fibrosis research.
-
Angiotensin III (human, mouse): Reliable RAAS Assay Solution
2026-06-17
This article addresses common laboratory challenges in RAAS-focused cell assays, detailing how 'Angiotensin III (human, mouse)' (SKU A1043) enables reproducible, data-backed research. Scenario-driven Q&A and protocol insights help bench scientists optimize their workflows using high-purity, well-characterized peptide standards.
-
Pemetrexed (SKU A4390): Reliable Antifolate for Cancer Assay
2026-06-16
This article dissects common laboratory challenges in cell viability and cytotoxicity studies, demonstrating how Pemetrexed (SKU A4390) from APExBIO provides reproducible results across cancer models. Grounded in peer-reviewed evidence and protocol optimization, it offers scenario-driven guidance to help researchers confidently select and use Pemetrexed in experimental workflows.
-
Clodronate Liposomes: Precision Macrophage Depletion in Vivo
2026-06-16
Clodronate Liposomes empower researchers to selectively deplete macrophages in vivo, unlocking new experimental clarity in immune modulation and therapy resistance studies. This guide delivers advanced workflows, troubleshooting advice, and real-world protocol enhancements to maximize the impact of APExBIO’s liposome-encapsulated clodronate platform.
-
PD 173074 in Epigenetic Oncology: FGFR1 Inhibition Beyond Ta
2026-06-15
Explore how PD 173074 enables advanced research on FGFR1 signaling, epigenetic regulation, and leukemia therapy. This article reveals unique insights into assay design and the translational impact of FGFR1 inhibition.
-
Protease Inhibitor Cocktail: Precision in Protein Extraction
2026-06-15
Safeguard your protein samples with the APExBIO Protease Inhibitor Cocktail (100X in DMSO, EDTA plus), engineered for robust degradation prevention in advanced cell and molecular workflows. This guide details optimized protocols, trouble-shooting strategies, and the translational impact of recent research connecting protease inhibition to reproducible, high-integrity data in cancer biology.
-
Cell lysis buffer for WB and IP: Optimizing Protein Extracti
2026-06-14
Unlock high-yield, artifact-free protein extraction from even the most challenging tissues using APExBIO's Cell lysis buffer for WB and IP. This guide translates recent tumor microenvironment discoveries into actionable workflows, with advanced troubleshooting and best-in-class inhibitor protection for demanding immunoprecipitation or Western blotting applications.